{"product_id":"lannett-five-forces-analysis","title":"Lannett Company Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLannett faces moderate buyer power and pricing pressure amid commoditized generics, while supplier leverage is limited by multiple API sources; regulatory scrutiny and patent cliffs raise the threat of substitutes and new entrants, and rivalry is intense among cost-focused competitors. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Lannett Company’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive Pharmaceutical Ingredient Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett depends on specialized third-party makers for about 60% of its active pharmaceutical ingredients (APIs), so supplier disruptions or a 10–20% raw material price rise immediately raise COGS and compress margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers must follow Current Good Manufacturing Practices (cGMP) to stay viable; as of 2025, FDA warning letters to API manufacturers fell 12% year-over-year, tightening the compliant pool. A supplier with a clean record for complex molecules gains leverage over generics like Lannett, which reported 2024 revenues of $426 million and cannot risk contamination-related recalls. The limited number of high-quality cGMP suppliers lets them dictate prices and prioritize larger pharma contracts, raising Lannett’s input-cost and supply-risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe global market for several chemical precursors used in generics is highly concentrated, with roughly 60–75% of supply coming from large manufacturers in India and China, limiting Lannett Company’s bargaining power for long-term contracts.\u003c\/p\u003e\n\u003cp\u003eAs a result, Lannett faces constrained negotiation leverage and must often accept supplier-led price terms for high-demand inputs.\u003c\/p\u003e\n\u003cp\u003eRegional shocks—like China’s 2021 environmental cuts that raised API (active pharmaceutical ingredient) prices by ~25%—can force sudden cost increases Lannett must absorb, squeezing margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing Equipment Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLannett’s move into complex generics and biosimilars needs specialized manufacturing equipment and vendor technical support, creating supplier power because only a few firms sell the needed proprietary bioprocessors and high-containment reactors.\u003c\/p\u003e\n\u003cp\u003eMaintenance, calibration, and software-update contracts often run multi-year and can cost 5–10% of equipment value annually, locking Lannett into high-priced relationships and raising operating leverage.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eFew qualified suppliers for bioprocessors\u003c\/li\u003e\n\u003cli\u003eMulti-year service contracts common\u003c\/li\u003e\n\u003cli\u003eMaintenance ≈5–10% of capex\/year\u003c\/li\u003e\n\u003cli\u003eSwitching costs high due to proprietary software\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForward Integration Threats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge API makers like Pfizer CentreOne and Thermo Fisher have been expanding into finished dosage forms, raising forward-integration risk that could make them direct rivals to Lannett and reduce supplier price flexibility.\u003c\/p\u003e\n\u003cp\u003eThis trend pressures Lannett to deepen supplier ties or diversify: in 2024 contract concentrations showed top 3 API vendors supplying ~62% of small-molecule inputs, so losing preferential terms would hit margins.\u003c\/p\u003e\n\u003cp\u003eMitigation options include dual sourcing, backward-looking NPV on insourced lines, or long-term purchase agreements to lock prices and capacity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop 3 vendors ≈62% supply concentration (2024)\u003c\/li\u003e\n\u003cli\u003eForward integration increases competitive supplier pricing\u003c\/li\u003e\n\u003cli\u003eMitigate via dual sourcing, long-term contracts, selective insourcing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier concentration, India\/China reliance drives sharp COGS and margin risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett’s supplier power is high: ~60% of APIs outsourced, top 3 vendors ≈62% (2024), and 60–75% of key precursors from India\/China, so price rises of 10–25% (historical shocks) quickly hit COGS and margins. cGMP-compliant suppliers fell after fewer FDA warnings in 2025, tightening quality pool; specialized bioprocess equipment and 5–10%\/yr service contracts raise switching costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs outsourced\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-3 vendor share (2024)\u003c\/td\u003e\n\u003ctd\u003e≈62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecursor sourcing\u003c\/td\u003e\n\u003ctd\u003e60–75% India\/China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice shock range\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService cost (equipment)\u003c\/td\u003e\n\u003ctd\u003e5–10% capex\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Lannett Company, this Porter's Five Forces overview uncovers key competitive drivers, supplier and buyer influence on pricing, entry barriers protecting incumbents, substitute threats, and disruptive forces shaping market share and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Lannett—quickly gauge competitive intensity and regulatory risk to inform portfolio or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Wholesale Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA vast majority of Lannett’s sales pass through the Big Three wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—who in 2024 controlled about 80% of U.S. pharmaceutical distribution, giving them outsized leverage over pricing and terms.\u003c\/p\u003e\n\u003cp\u003eThese distributors can demand steep discounts and extended payment terms; industry data show median generic manufacturer gross-margin compression of 200–400 basis points when selling via the Big Three.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organization Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGPOs aggregate purchasing for ~1,600 US hospitals and negotiate deep discounts on generics; in 2024 GPO-contracted generics often saw price cuts of 20–40%, pressuring manufacturers like Lannett (ticker: LCI) to accept thin margins to secure volume.\u003c\/p\u003e\n\u003cp\u003eBecause GPOs can steer volume, losing a major contract can cut product market share by 10–30% within 12 months; Lannett’s revenue exposure is acute for top SKUs where GPO channels account for \u0026gt;40% of sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail pharmacy consolidation—CVS Health, Walgreens Boots Alliance, and Kroger together held ~45% of US prescription retail market in 2024—gives buyers scale to negotiate directly with manufacturers or preferred wholesalers, squeezing supplier pricing power.\u003c\/p\u003e\n\u003cp\u003eThese chains are highly price-sensitive and routinely switch between generics for cents-per-pill differences, turning many Lannett products into commodities and forcing aggressive price competition.\u003c\/p\u003e\n\u003cp\u003eAs a result Lannett’s gross margins compressed: industry generic margins fell to ~18% in 2024, pressuring Lannett to cut prices or incur volume-driven margin erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Payer Pricing Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGovernment programs and large private payers increasingly enforce restrictive formularies and price caps; CMS inflation caps and state Medicaid rebates cut generic reimbursements, pressuring margins.\u003c\/p\u003e\n\u003cp\u003eThese buyers leverage scale to demand rebates and lower list prices for interchangeable generics; in 2024 Medicare Part D negotiations pushed net prices down ~6–8% for oral generics.\u003c\/p\u003e\n\u003cp\u003eLannett’s revenue is highly sensitive to these shifts—30–45% of U.S. generic volumes tied to institutional contracts—so reimbursement changes materially affect cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare\/Medicaid and large PBMs drive price caps\u003c\/li\u003e\n\u003cli\u003e2024 net price declines ≈6–8% for generics\u003c\/li\u003e\n\u003cli\u003e30–45% of Lannett U.S. volumes in institutional contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for End Users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePharmacists and patients treat generics as identical, so Lannett faces negligible brand loyalty and high customer price sensitivity; 2024 IMS Health data showed generics accounted for 90% of U.S. prescriptions, amplifying switching risk.\u003c\/p\u003e\n\u003cp\u003eBecause customers switch immediately for lower prices, Lannett must track competitors’ list and net prices daily; a 5% price gap can shift volume quickly in commoditized molecules where margins are thin.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eGenerics = 90% U.S. Rx (2024)\u003c\/li\u003e\n\u003cli\u003eLow differentiation → instant switching\u003c\/li\u003e\n\u003cli\u003eMonitor competitor pricing daily\u003c\/li\u003e\n\u003cli\u003eSmall price gaps (≈5%) move volume\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ Clout Crushes Generics: Big Three, Retail Chains Drive Price \u0026amp; Margin Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold strong power: three wholesalers controlled ~80% of U.S. pharma distribution in 2024, retail chains ~45% of prescriptions, and 30–45% of Lannett’s volumes sit in institutional contracts, driving 6–8% net-price declines and 200–400 bp margin compression for generics; low differentiation makes customers price-sensitive and quick to switch on ~5% price gaps.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig Three share\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail chains share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional volume (LCI)\u003c\/td\u003e\n\u003ctd\u003e30–45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric net-price decline\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin compression\u003c\/td\u003e\n\u003ctd\u003e200–400 bp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice gap that shifts volume\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eLannett Company Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of The Lannett Company you’ll receive immediately after purchase—no samples or placeholders, fully formatted and ready to use. The document covers supplier and buyer power, competitive rivalry, threat of substitutes, and barriers to entry with concise, actionable insights. Once bought, you’ll get this identical file for download and application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746746642809,"sku":"lannett-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lannett-five-forces-analysis.png?v=1772191463","url":"https:\/\/growthsharematrix.com\/products\/lannett-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}